In the wake of the novel Covid-19 disease pandemic, the global economy has been affected and health crises are widespread. The disease is still incurable, and no effective treatment exists for it. During the Covid-19 crisis, drug repurposing has proven to be an effective treatment strategy. Drug repositioning is an approach to finding effective drugs for treating new diseases by discovering new efficacy of existing drugs. Studies on drug-virus association can reveal new efficacy. The antiviral drug repositioning problem is defined here as a matrix completion problem in which antiviral drugs go down the rows, while viruses go down the columns. We propose a hybrid model called AutoMF that identifies new drug–virus association. This new hybrid model aims to develop a matrix factorization model with deep learning and use it to predict drug-virus associations for repositioning drugs. In our model, a heterogeneous drug–virus network is used, which combines drug–virus associations, drug-drug similarity matrix, and virus-virus similarity matrix. Matrix factorization can extract latent factors from the drug-virus associations. The sparse nature of the associations may prevent the latent factors from being very effective. To solve this problem, deep learning is used to learn effective latent representations from similarity matrices to incorporate with MF to enhance their latent factor priors. Our model outperforms several recent approaches in comparison to benchmarking tests performed on the DVA dataset. In our approach, we identify antiviral drugs currently being tested in clinical trials or those used currently to treat patients.
Read full abstract